This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


This webinar will address current concepts in the realm of cell free DNA testing for cancer, with an emphasis on the role of plasma-based testing in patients with non-small cell lung carcinoma. Topics to be covered include: the process for validating and implementing cfDNA testing in the hospital setting, the clinical role for cfDNA testing in cancer patients with an emphasis on EGFR-mutated lung carcinoma, and approaches to next-generation sequencing for cfDNA. Practical issues will be emphasized, including clinical performance characteristics of available assays and specimen handling considerations. Selected studies demonstrating the future potential of cfDNA testing for cancer monitoring will be reviewed.

Speaker: Lynette M. Sholl, MD

Host: Anthony Snow, MD

Duration: 1 hr

Level of Instruction: Basic

If you would like continuing education credit, click on the links below.

Credit Type Number of Credit Hours Click on link to purchase:

Purchase CME/CMLE

(Free for AMP members)

SAM 1.0

Purchase SAM

(Free for AMP members)

Continuing Education Credit must be purchased and claimed by October 26, 2020


* You may not submit SAMs and CME/CMLE credit for the same content.

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Course Information
Course Date:
September 25, 2017
Course Objectives
  • Describe approaches to cfDNA assay design and validation.
  • Describe the clinical need for alternatives to tumor tissue testing and the current role for cell free DNA diagnostics in lung cancer.
  • Identify the challenges of validation and implementation of cfDNA testing in the clinical laboratory.
  • Describe the utility and approach of targeted genotyping versus next generation sequencing from cfDNA.
Cell Free DNA Testing for Cancer: Clinical Validation, Implementation and Applications
Speaker Information
Lynette M. Sholl MD   [ view bio ]
Individual topic purchase: Selected
Webinar Only
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $195.00